Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth

Table 1 Comparative analysis of hepatic tuftelin 1 immunohistochemical staining and expressing intensity between hepatocellular carcinoma and their para-cancerous tissues

Group	n	TUFT1		χ2 value	P value	TUFT1 score				Z value	P value
		Neg.	Pos.			0	1	2	3
HCC	132	17	115	18.563	< 0.001	17	49	55	11	4.911	< 0.001
Non-HCC	132	47	85			47	54	23	8

HCC: Hepatocellular carcinoma; Neg: Negative; Non-HCC: Non-cancerous tissue; Pos: Positive; TUFT1: Tuftelin 1.

Table 2 Relationship between tuftelin 1 and clinicopathological characteristics in hepatocellular carcinoma patients

Group	n	TUFT1 expression		Pearson χ2	P value
		Low	High
AFP (ng/mL)				2.901	0.089
< 20	28	18	10
≥ 20	104	48	56
HBsAg				3.300	0.069
Neg.	12	9	3
Pos.	120	57	63
HBeAg				4.080	0.043
Neg.	87	49	38
Pos.	45	17	28
Tumor size (cm)				9.388	0.002
< 3	26	20	6
≥ 3	106	46	60
Differentiation degree				3.013	0.083
Well-Med.	19	13	6
Poor	113	53	60
Vascular invasion				14.885	< 0.001
With	58	18	40
Without	74	48	26
Ascites				5.940	0.015
With	32	10	22
Without	100	56	44
TNM staging				13.516	< 0.001
I-II	59	40	19
III-IV	73	26	47

AFP: Alpha-fetoprotein; HBeAg: Hepatitis B virus e antigen; HBsAg: Hepatitis B virus surface antigen; HCC: Hepatocellular carcinoma; Neg: Negative expression; Pos: Positive expression; TUFT1: Tuftelin 1.

Table 3 Univariate and multivariate analysis of tuftelin 1 in the prognosis of hepatocellular carcinoma

Group	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
TUFT1 expression, high vs low	3.026	1.927-4.752	< 0.001	1.743	1.044-2.910	0.034
AFP (ng/mL), ≥ 20 vs < 20	1.866	1.066-3.266	0.027	1.482	0.835-2.630	0.178
HBsAg, pos. vs neg.	1.495	0.652-3.431	0.339
HBeAg, pos. vs neg.	1.670	1.084-2.574	0.019	1.070	0.659-1.739	0.784
Tumor size (cm), ≥ 3 vs < 3	3.680	1.837-7.370	< 0.001	2.235	1.043-4.485	0.039
Differentiation degree, Poor vs well-med.	1.642	0.869-3.100	0.123
Vascular invasion, with vs without	3.297	2.133-5.094	< 0.001	2.018	1.186-3.434	0.010
Ascites, with vs without	2.592	1.648-4.076	< 0.001	1.929	1.177-3.161	0.009
TNM staging, III-IV vs I-II	2.411	1.532-3.796	< 0.001	1.110	0.614-2.005	0.731

AFP: Alpha-fetoprotein; HBeAg: hepatitis B virus e antigen; HBsAg: hepatitis B virus surface antigen; HR: Hazard ratio; Neg: Negative expression; Pos: Positive expression; TNM: Tumor-node-metastasis.